S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
The only accurate crypto trading system I know … (Ad)
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
The only accurate crypto trading system I know … (Ad)
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
The only accurate crypto trading system I know … (Ad)
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The “Perfect Storm” for Gold (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
The only accurate crypto trading system I know … (Ad)
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Free Trial

Maravai LifeSciences (MRVI) Earnings Date, Estimates & Call Transcripts

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)
Free MRVI Stock Alerts
$7.73
-0.41 (-5.04%)
(As of 04/17/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 8
After Market Closes
Confirmed
Actual EPS
(Feb. 22)
-$0.05 Missed By -$0.01
Consensus EPS
(Feb. 22)
-$0.04
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

MRVI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MRVI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Maravai LifeSciences Analyst EPS Estimates

Current Year EPS Consensus Estimate:($0.15) EPS
Next Year EPS Consensus Estimate: ($0.11) EPS

MRVI Earnings Date and Information

Maravai LifeSciences last announced its earnings data on February 22nd, 2024. The reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The company earned $74.14 million during the quarter, compared to the consensus estimate of $62.99 million. Maravai LifeSciences has generated ($0.90) earnings per share over the last year (($0.90) diluted earnings per share). Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.15) to ($0.11) per share. Maravai LifeSciences has confirmed that its next quarterly earnings report will be published on Wednesday, May 8th, 2024. Maravai LifeSciences will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call..

Maravai LifeSciences Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/8/2024
Confirmed)		-------  
2/22/2024Q4 2023($0.04)($0.05)($0.01)$0.70$62.99 million$74.14 million
11/7/2023Q3 2023($0.03)($0.02)+$0.01$0.01$75.23 million$66.87 million
8/7/2023Q2 2023($0.02)($0.06)($0.04)($0.07)$70.30 million$68.91 million
5/8/2023Q1 2023$0.04$0.03($0.01)$0.06$79.72 million$79.03 million    
2/22/2023Q4 2022$0.34$0.35+$0.01$0.42$204.95 million$204.70 million    
11/2/2022Q3 2022$0.32$0.37+$0.05$0.40$193.83 million$191.26 million
8/4/2022Q2 2022$0.45$0.54+$0.09$0.55$234.91 million$242.73 million
5/5/2022Q1 2022$0.43$0.54+$0.11$0.58$232.29 million$244.30 million    
2/23/2022Q4 2021$0.38$0.45+$0.07$0.48$208.09 million$228.44 million    
11/10/2021Q3 2021$0.35$0.44+$0.09$0.65$199.68 million$204.81 million    
8/10/2021Q2 2021$0.32$0.44+$0.12$0.44$195.49 million$217.80 million    
5/10/2021Q1 2021$0.19$0.26+$0.07$0.28$135.36 million$148.20 million  

Maravai LifeSciences Earnings - Frequently Asked Questions

When is Maravai LifeSciences's earnings date?

Maravai LifeSciences has confirmed that its next quarterly earnings data will be published on Wednesday, May 8th, 2024. Learn more on MRVI's earnings history.

Did Maravai LifeSciences beat their earnings estimates last quarter?

In the previous quarter, Maravai LifeSciences (NASDAQ:MRVI) missed the analysts' consensus estimate of ($0.04) by $0.01 with a reported earnings per share (EPS) of ($0.05). Learn more on analysts' earnings estimate vs. MRVI's actual earnings.

How much revenue does Maravai LifeSciences generate each year?

Maravai LifeSciences (NASDAQ:MRVI) has a recorded annual revenue of $288.95 million.

How much profit does Maravai LifeSciences generate each year?

Maravai LifeSciences (NASDAQ:MRVI) has a recorded net income of -$119.03 million. MRVI has generated -$0.90 earnings per share over the last four quarters.

What is Maravai LifeSciences's EPS forecast for next year?

Maravai LifeSciences's earnings are expected to grow from ($0.15) per share to ($0.11) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:MRVI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
The “Perfect Storm” for Gold
Gold Safe Exchange
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
Biden out June 13; Kamala won’t replace him?
Paradigm Press
Your Money is Not Safe
American Alternative